The PopVax Chronicles

The PopVax Chronicles

Home
Archive
About
Potent, broadly-protective flu vaccines to protect against potential pandemic influenza viruses such as H5N1
PopVax’s influenza vaccine designs elicit as much as 250x greater antibody titer against seasonal strains than existing approved flu vaccines, as well…
Jan 3 • Soham Sankaran
PopVax updates – NIH NIAID will conduct the Phase I trial for our COVID-19 vaccine + Gates Foundation funding for our thermostable mRNA…
We have some exciting news to share:
Dec 22, 2024 • PopVax
The unlikely, inevitable founding of PopVax, Part I: Three meetings and six million funerals
Broadly-protective mRNA vaccines to save millions of lives
Aug 20, 2023 • Soham Sankaran
The PopVax Chronicles
The PopVax Chronicles
What it takes to develop, manufacture, test, and deploy broadly-protective mRNA vaccines
Links
PopVax.com
Jobs at PopVax
@PopVaxIndia on X/Twitter
PopVax on Bluesky
PopVax on Linkedin
PopVax YouTube Channel

The PopVax Chronicles

AboutArchiveSitemap
© 2025 PopVax · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture